ClinicalTrials.gg
CompletedNCT04977336Updated Jun 25, 2025Results posted

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

A Phase 2 interventional study of VX-548 and HB/APAP in Acute Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 12 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
274
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing suzetrigine in Acute Pain — 3 open to participants now, 3 under way, none of them phase 3. suzetrigine · Acute Pain.

Enrollment
4th of 10
274 · median 165
Started
2021
with 1 other
Phase 2
2 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
6 of 10
Vertex Pharmaceuticals Incorporated

Among the 10 studies testing suzetrigine in Acute Pain, this one is the 4th largest by enrollment, is one of 2 that started in 2021, is one of 2 in phase 2, and was the 1st registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.

Browse Acute Pain studies →

Open to participants now

3 of the 10 studies testing suzetrigine in Acute Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About suzetrigine

suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing suzetrigine in Acute Pain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating acute pain after a bunionectomy.

03

Conditions studied

  • Acute Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Before Surgery:

    • Participant scheduled to undergo a primary unilateral bunionectomy with distal first metatarsal osteotomy (i.e., Austin procedure) and internal fixation under regional anesthesia (Mayo and popliteal sciatic block)
  • After Surgery:

    • Participant is lucid and able to follow commands
    • All analgesic guidelines were followed during and after the bunionectomy

Key Exclusion Criteria:

  • Before Surgery:

    • Prior history of bunionectomy or other foot surgery on the index foot
    • History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
    • Any prior surgery within 1 month before the first study drug
  • After Surgery:

    • Participant had a Type 3 deformity requiring a base wedge osteotomy or concomitant surgery such as hammertoe repair, or had medical complications during the bunionectomy that, in the opinion of the investigator, should preclude randomization

Other protocol defined Inclusion/Exclusion criteria may apply.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
274 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo matched to VX-548 and Hydrocodone bitartrate/acetaminophen (HB/APAP) for 2 days.

    Drug: Placebo (matched to VX-548) · Drug: Placebo (matched to HB/APAP)

  • Active comparator
    HB/APAP

    Participants received HB 5 milligrams (mg)/ APAP 325 mg every 6 hours (q6h) for 2 days.

    Drug: HB/APAP

  • Experimental
    VX-548: Low Dose

    Participants received VX-548 20 mg as first dose, followed by VX-548 10 mg tablet every 12 hours (q12h) for 2 days.

    Drug: VX-548

  • Experimental
    VX-548: Mid Dose

    Participants received VX-548 60 mg as first dose, followed by VX-548 30 mg q12h for 2 days.

    Drug: VX-548

  • Experimental
    VX-548: High Dose

    Participants received VX-548 100 mg as first dose, followed by VX-548 50 mg q12h for 2 days.

    Drug: VX-548

Interventions

  • DrugVX-548

    Tablets for oral administration.

    Also known as: Suzetrigine

  • DrugHB/APAP

    Drug pages: Hydrocodone · Acetaminophen

    Capsules for oral administration.

  • DrugPlacebo (matched to VX-548)

    Placebo matched to VX-548 for oral administration.

  • DrugPlacebo (matched to HB/APAP)

    Placebo matched to HB/APAP for oral administration.

06

What researchers measure

Primary outcomes

  1. Time-Weighted Sum of Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) 0 to 48 Hours (SPID48) After the First Dose of Study Drug

    SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the pain intensity score at given post-dose time points from the baseline pain intensity scores (using pain rating score range: 0= no pain to 10= worst possible pain). SPID48 was calculated from 0 to 48 hours and the score range was -480 (worst score) to 480 (best score).

    Time frame: 0 to 48 hours After First Dose of Study Drug

Secondary outcomes

  1. Time-Weighted SPID as Recorded on a NPRS 0 to 24 Hours (SPID24) After the First Dose of Study Drug

    SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the pain intensity score at given post-dose time points from the baseline pain intensity scores (using pain rating score range: 0= no pain to 10= worst possible pain). SPID24 was calculated from 0 to 24 hours and the score range was -240 (worst score) to 240 (best score).

    Time frame: 0 to 24 hours After First Dose of Study Drug

  2. Percentage of Participants With at Least 30 Percent (%) Reduction in NPRS at 48 Hours After the First Dose of Study Drug

    Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with at least 30% reduction from baseline in NPRS at 48 hours after the first dose of VX-548, HB/APAP or placebo was reported.

    Time frame: From Baseline at 48 Hours After First Dose of Study Drug

  3. Percentage of Participants With at Least 50% Reduction in NPRS at 48 Hours After the First Dose of Study Drug

    Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with at least 50% reduction from baseline in NPRS at 48 hours after the first dose of VX-548, HB/APAP or placebo were reported.

    Time frame: From Baseline at 48 Hours After First Dose of Study Drug

  4. Percentage of Participants With at Least 70% Reduction in NPRS at 48 Hours After the First Dose of Study Drug

    Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with at least 70% reduction from baseline in NPRS at 48 hours after the first dose of VX-548, HB/APAP or placebo were reported.

    Time frame: From Baseline at 48 Hours After First Dose of Study Drug

  5. Maximum Observed Plasma Concentration (Cmax) of VX-548 and M6-548 (Metabolite)

    Time frame: Day 1 and Day 2

  6. Time to Reach Maximum Observed Plasma Concentration (Tmax) of VX-548 and M6-548 (Metabolite)

    Time frame: Day 1 and Day 2

  7. Area Under the Concentration Versus Time Curve From 0 to 12 Hours (AUC0-12h) of VX-548 and M6-548 (Metabolite)

    Time frame: Day 1 and Day 2

  8. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Day 16

07

Results

Posted Jun 25, 2025

Participant flow

Participant flow — Overall Study
MilestonePlaceboHB/APAPVX-548: Low DoseVX-548: Mid DoseVX-548: High Dose
Started5960336260
Completed5860326158
Not completed10112
Withdrew: Withdrawal of consent (not due to ae)10012
Withdrew: Lost to follow-up00100

Outcome measures

PrimaryTime-Weighted Sum of Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) 0 to 48 Hours (SPID48) After the First Dose of Study Drug

SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the pain intensity score at given post-dose time points from the baseline pain intensity scores (using pain rating score range: 0= no pain to 10= worst possible pain). SPID48 was calculated from 0 to 48 hours and the score range was -480 (worst score) to 480 (best score).

Time frame:
0 to 48 hours After First Dose of Study Drug
Reported as:
Least squares mean · units on a scale
Time-Weighted Sum of Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) 0 to 48 Hours (SPID48) After the First Dose of Study Drug
units on a scalePlaceboHB/APAPVX-548: Low DoseVX-548: Mid DoseVX-548: High Dose
Time-Weighted Sum of Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) 0 to 48 Hours (SPID48) After the First Dose of Study Drug100.98 ± 11.60115.64 ± 11.49112.92 ± 15.5286.87 ± 11.33137.77 ± 11.50
Statistical analysis
  • Placebo vs HB/APAP · ANCOVA · p = 0.3706
  • Placebo vs VX-548: Low Dose · ANCOVA · p = 0.5379
  • Placebo vs VX-548: Mid Dose · ANCOVA · p = 0.3859
  • Placebo vs VX-548: High Dose · ANCOVA · p = 0.0251
SecondaryTime-Weighted SPID as Recorded on a NPRS 0 to 24 Hours (SPID24) After the First Dose of Study Drug

SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the pain intensity score at given post-dose time points from the baseline pain intensity scores (using pain rating score range: 0= no pain to 10= worst possible pain). SPID24 was calculated from 0 to 24 hours and the score range was -240 (worst score) to 240 (best score).

Time frame:
0 to 24 hours After First Dose of Study Drug
Reported as:
Least squares mean · units on a scale
Time-Weighted SPID as Recorded on a NPRS 0 to 24 Hours (SPID24) After the First Dose of Study Drug
units on a scalePlaceboHB/APAPVX-548: Low DoseVX-548: Mid DoseVX-548: High Dose
Time-Weighted SPID as Recorded on a NPRS 0 to 24 Hours (SPID24) After the First Dose of Study Drug31.54 ± 5.5740.95 ± 5.5234.36 ± 7.4524.78 ± 5.4445.22 ± 5.52
Statistical analysis
  • Placebo vs HB/APAP · ANCOVA · p = 0.2318
  • Placebo vs VX-548: Low Dose · ANCOVA · p = 0.7615
  • Placebo vs VX-548: Mid Dose · ANCOVA · p = 0.3870
  • Placebo vs VX-548: High Dose · ANCOVA · p = 0.0823
SecondaryPercentage of Participants With at Least 30 Percent (%) Reduction in NPRS at 48 Hours After the First Dose of Study Drug

Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with at least 30% reduction from baseline in NPRS at 48 hours after the first dose of VX-548, HB/APAP or placebo was reported.

Time frame:
From Baseline at 48 Hours After First Dose of Study Drug
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 30 Percent (%) Reduction in NPRS at 48 Hours After the First Dose of Study Drug
percentage of participantsPlaceboHB/APAPVX-548: Low DoseVX-548: Mid DoseVX-548: High Dose
Percentage of Participants With at Least 30 Percent (%) Reduction in NPRS at 48 Hours After the First Dose of Study Drug67.868.375.862.983.3
Statistical analysis
  • Placebo vs HB/APAP · Cochran-Mantel-Haenszel · p = 0.9986
  • Placebo vs VX-548: Low Dose · Cochran-Mantel-Haenszel · p = 0.4446
  • Placebo vs VX-548: Mid Dose · Cochran-Mantel-Haenszel · p = 0.5978
  • Placebo vs VX-548: High Dose · Cochran-Mantel-Haenszel · p = 0.0479
SecondaryPercentage of Participants With at Least 50% Reduction in NPRS at 48 Hours After the First Dose of Study Drug

Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with at least 50% reduction from baseline in NPRS at 48 hours after the first dose of VX-548, HB/APAP or placebo were reported.

Time frame:
From Baseline at 48 Hours After First Dose of Study Drug
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 50% Reduction in NPRS at 48 Hours After the First Dose of Study Drug
percentage of participantsPlaceboHB/APAPVX-548: Low DoseVX-548: Mid DoseVX-548: High Dose
Percentage of Participants With at Least 50% Reduction in NPRS at 48 Hours After the First Dose of Study Drug61.061.772.756.566.7
Statistical analysis
  • Placebo vs HB/APAP · Cochran-Mantel-Haenszel · p = 0.9895
  • Placebo vs VX-548: Low Dose · Cochran-Mantel-Haenszel · p = 0.2731
  • Placebo vs VX-548: Mid Dose · Cochran-Mantel-Haenszel · p = 0.6492
  • Placebo vs VX-548: High Dose · Cochran-Mantel-Haenszel · p = 0.5119
SecondaryPercentage of Participants With at Least 70% Reduction in NPRS at 48 Hours After the First Dose of Study Drug

Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with at least 70% reduction from baseline in NPRS at 48 hours after the first dose of VX-548, HB/APAP or placebo were reported.

Time frame:
From Baseline at 48 Hours After First Dose of Study Drug
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 70% Reduction in NPRS at 48 Hours After the First Dose of Study Drug
percentage of participantsPlaceboHB/APAPVX-548: Low DoseVX-548: Mid DoseVX-548: High Dose
Percentage of Participants With at Least 70% Reduction in NPRS at 48 Hours After the First Dose of Study Drug40.750.051.538.751.7
Statistical analysis
  • Placebo vs HB/APAP · Cochran-Mantel-Haenszel · p = 0.3158
  • Placebo vs VX-548: Low Dose · Cochran-Mantel-Haenszel · p = 0.3247
  • Placebo vs VX-548: Mid Dose · Cochran-Mantel-Haenszel · p = 0.8424
  • Placebo vs VX-548: High Dose · Cochran-Mantel-Haenszel · p = 0.2312
SecondaryMaximum Observed Plasma Concentration (Cmax) of VX-548 and M6-548 (Metabolite)
Time frame:
Day 1 and Day 2
Reported as:
Mean · micrograms/milliliter (mcg/mL)
Maximum Observed Plasma Concentration (Cmax) of VX-548 and M6-548 (Metabolite)
micrograms/milliliter (mcg/mL)VX-548: Low DoseVX-548: Mid DoseVX-548: High Dose
VX-548: Day 10.119 ± 0.05360.311 ± 0.08640.523 ± 0.193
VX-548: Day 20.118 ± 0.04260.337 ± 0.09510.503 ± 0.126
M6-548: Day 10.0929 ± 0.03630.234 ± 0.07810.385 ± 0.114
M6-548: Day 20.183 ± 0.05200.483 ± 0.1300.787 ± 0.210
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of VX-548 and M6-548 (Metabolite)
Time frame:
Day 1 and Day 2
Reported as:
Median · hours (h)
Time to Reach Maximum Observed Plasma Concentration (Tmax) of VX-548 and M6-548 (Metabolite)
hours (h)VX-548: Low DoseVX-548: Mid DoseVX-548: High Dose
VX-548: Day 12.20 (0.967 to 6.00)2.17 (1.00 to 5.98)2.09 (1.00 to 6.03)
VX-548: Day 21.93 (0.867 to 7.87)1.97 (0.850 to 6.00)2.00 (0.667 to 5.98)
M6-548: Day 16.00 (1.08 to 12.0)5.95 (2.00 to 12.2)6.02 (1.92 to 12.1)
M6-548: Day 25.88 (1.00 to 8.05)4.28 (1.00 to 12.0)4.20 (1.70 to 12.0)
SecondaryArea Under the Concentration Versus Time Curve From 0 to 12 Hours (AUC0-12h) of VX-548 and M6-548 (Metabolite)
Time frame:
Day 1 and Day 2
Reported as:
Mean · hour*mcg/ml (h*mcg/mL)
Area Under the Concentration Versus Time Curve From 0 to 12 Hours (AUC0-12h) of VX-548 and M6-548 (Metabolite)
hour*mcg/ml (h*mcg/mL)VX-548: Low DoseVX-548: Mid DoseVX-548: High Dose
VX-548: Day 10.650 ± 0.1731.84 ± 0.4512.95 ± 0.745
VX-548: Day 20.885 ± 0.2482.54 ± 0.7313.72 ± 0.873
M6-548: Day 10.845 ± 0.3372.23 ± 0.7533.53 ± 1.13
M6-548: Day 21.94 ± 0.5775.12 ± 1.418.27 ± 2.16
SecondarySafety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Day 16
Reported as:
Count of participants · Participants
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPlaceboHB/APAPVX-548: Low DoseVX-548: Mid DoseVX-548: High Dose
Participants with TEAEs232571718
Participants with SAEs00000

Adverse events

Collected over Day 1 up to Day 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/59 (0%)0/59 (0%)12/59 (20.3%)
HB/APAP0/60 (0%)0/60 (0%)13/60 (21.7%)
VX-548: Low Dose0/33 (0%)0/33 (0%)2/33 (6.1%)
VX-548: Mid Dose0/62 (0%)0/62 (0%)7/62 (11.3%)
VX-548: High Dose0/60 (0%)0/60 (0%)9/60 (15%)
Most frequent other events
Most frequent other events
EventPlaceboHB/APAPVX-548: Low DoseVX-548: Mid DoseVX-548: High Dose
NauseaGastrointestinal disorders5/5911/602/333/625/60
HeadacheNervous system disorders7/594/600/334/625/60
VomitingGastrointestinal disorders1/593/600/330/620/60

Baseline characteristics

Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboHB/APAPVX-548: Low DoseVX-548: Mid DoseVX-548: High DoseTotal
Mean47.8 ± 13.650.0 ± 12.547.8 ± 15.548.3 ± 13.147.6 ± 13.748.4 ± 13.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboHB/APAPVX-548: Low DoseVX-548: Mid DoseVX-548: High DoseTotal
Female4950255753234
Male101085740
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboHB/APAPVX-548: Low DoseVX-548: Mid DoseVX-548: High DoseTotal
Hispanic or Latino17226202186
Not Hispanic or Latino4238274239188
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboHB/APAPVX-548: Low DoseVX-548: Mid DoseVX-548: High DoseTotal
American Indian or Alaska Native100023
Asian332019
Native Hawaiian or Other Pacific Islander000000
Black or African American13139171466
White4144224442193
More than one race100113
Unknown or Not Reported000000
Pain Intensity at Baseline (at 0 hours) as Recorded on Numeric Pain Rating Scale (NPRS)
Pain Intensity at Baseline (at 0 hours) as Recorded on Numeric Pain Rating Scale (NPRS)(units on a scale)PlaceboHB/APAPVX-548: Low DoseVX-548: Mid DoseVX-548: High DoseTotal
Mean6.9 ± 1.76.9 ± 1.96.9 ± 1.86.6 ± 1.86.7 ± 1.76.8 ± 1.8
08

Study locations

12 sites
  • Shoals Medical Trials Inc.
    Sheffield, Alabama 35660, United States
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
  • Lotus Clinical Research
    Pasadena, California 91105, United States
  • New Hope Research Development
    Tarzana, California 91356, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Chesapeake Research Group
    Pasadena, Maryland 21122, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • First Surgical Hospital
    Bellaire, Texas 77401, United States
  • Legent Orthopedic Hospital
    Carrollton, Texas 75006, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78229, United States
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
09

References and documents

Publications

  • Jones J, Correll DJ, Lechner SM, Jazic I, Miao X, Shaw D, Simard C, Osteen JD, Hare B, Beaton A, Bertoch T, Buvanendran A, Habib AS, Pizzi LJ, Pollak RA, Weiner SG, Bozic C, Negulescu P, White PF; VX21-548-101 and VX21-548-102 Trial Groups. Selective Inhibition of NaV1.8 with VX-548 for Acute Pain. N Engl J Med. 2023 Aug 3;389(5):393-405. doi: 10.1056/NEJMoa2209870. PubMed 37530822 ↗
  • Russo MA, Baron R, Dickenson AH, Kern KU, Santarelli DM. Ambroxol for neuropathic pain: hiding in plain sight? Pain. 2023 Jan 1;164(1):3-13. doi: 10.1097/j.pain.0000000000002693. Epub 2022 May 17. PubMed 35580314 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Feb 2022, 6 months.

Results were first posted in Jun 2025, 3 years 4 months after primary completion. A results delay was requested in Feb 2023.

Of 40 phase 2 interventional studies under Acute Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2021
First posted
Jul 26, 2021
StartActual
Jul 19, 2021
Primary completionActual
Feb 17, 2022
CompletionActual
Mar 4, 2022
Results delay requested
Feb 16, 2023
Results first posted
Jun 25, 2025
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04977336
Responsible party
Sponsor
First posted
Jul 26, 2021
Start date
Jul 19, 2021
Primary completion
Feb 17, 2022
Completion
Mar 4, 2022
Results posted
Jun 25, 2025
Last update
Jun 25, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suzetrigine

Start the discussion